Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- BERSHOF E., OXMAN A. C. Agranulocytosis following use of phenylbutazone (butazolidin). J Am Med Assoc. 1953 Feb 14;151(7):557–558. doi: 10.1001/jama.1953.02940070023007b. [DOI] [PubMed] [Google Scholar]
- CUDKOWICZ L., JACOBS J. H. Phenylbutazone (butazolidine) in the treatment of chronic arthritis. Lancet. 1953 Jan 31;1(6753):223–224. doi: 10.1016/s0140-6736(53)90891-5. [DOI] [PubMed] [Google Scholar]
- DAVIES H. R., BARTER R. W., GEE A., HIRSON C. Observations on the use of butazolidin in arthritis. Br Med J. 1952 Dec 27;2(4799):1392–1394. [PMC free article] [PubMed] [Google Scholar]
- ETESS A. D., JACOBSON A. S. Fatality due to agranulocytosis following use of phenylbutazone (butazolidin). J Am Med Assoc. 1953 Feb 21;151(8):639–640. doi: 10.1001/jama.1953.02940080039009. [DOI] [PubMed] [Google Scholar]
- GREEN J., WILLIAMS P. O. Effect of butazolidine on the excretion of water and electrolytes. Lancet. 1953 Mar 21;1(6760):575–577. doi: 10.1016/s0140-6736(53)91698-5. [DOI] [PubMed] [Google Scholar]
- KUZELL W. C., SCHAFFARZICK R. W., BROWN B., MANKLE E. A. Phenylbutazone (butazolidin) in rheumatoid arthritis and gout. J Am Med Assoc. 1952 Jun 21;149(8):729–734. doi: 10.1001/jama.1952.02930250011004. [DOI] [PubMed] [Google Scholar]
- STIFEL J. L., BURNHEIMER J. C. Agranulocytosis following administration of phenylbutazone (butazolidin). J Am Med Assoc. 1953 Feb 14;151(7):555–556. doi: 10.1001/jama.1953.02940070021007. [DOI] [PubMed] [Google Scholar]